Diltiazem Hydrochloride Tablets

1 This product is a calcium channel blocker, and its action is related to the inhibition of calcium ion influx during myocardial and vascular smooth muscle depolarization. 2 This product can effectively dilate the epicardial and subendocardial coronary arteries, relieve spontaneous angina pectoris or angina pectoris caused by coronary artery spasm induced by ergonovine; by slowing down the heart rate and lowering blood pressure, it reduces myocardial oxygen demand, increases exercise tolerance and relieves exertional angina pectoris. 3 This product relaxes vascular smooth muscle, decreases peripheral vascular resistance and blood pressure. The extent of its blood pressure reduction is related to the degree of hypertension. For people with normal blood pressure, it only slightly decreases blood pressure. 4 This product has a negative inotropic effect and can slow down the conduction of the sinoatrial node and atrioventricular node. Carcinogenic, mutagenic and reproductive toxic effects have been reported. No carcinogenic effect was found in rats taking this product for 24 months and in mice taking this product for 21 months. No mutagenic effect was found in in vitro bacterial experiments. Animal experiments have confirmed that this product has no significant effect on fertility.

Main ingredients: cis-()-5-[(2-dimethylamino)ethyl]-2-(4-methoxyphenyl)-3-acetoxy-2,3-dihydro-1,5-phenylpropylthiazepine-4(5H)-one hydrochloride. Molecular formula: C22H26N2O4S?HCL, molecular weight: 450.99.

This product is white tablets.

1. Angina pectoris caused by coronary artery spasm and exertional angina pectoris. 2. Hypertension. 3. Hypertrophic cardiomyopathy.

Oral administration, starting at 30 mg/time, 4 times a day, before meals and before bedtime, increase the dose every 1-2 days until the best therapeutic effect is achieved. The average dose range is 90-360 mg/day.

Common: edema, headache, nausea, dizziness, rash, weakness. Rare: 1. Cardiovascular system: atrioventricular block, bradycardia, bundle branch block, congestive heart failure, abnormal ECG, hypotension, palpitations, syncope, tachycardia, ventricular premature beats. 2. Nervous system: dreaming, amnesia, depression, abnormal gait, hallucinations, insomnia, nervousness, paresthesia, personality changes, drowsiness, tremor. 3. Digestive system: anorexia, constipation, diarrhea, dysgeusia, indigestion, thirst, vomiting, weight gain, mild increase in alkaline phosphatase, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase. 4. Skin: petechiae, photosensitivity, itching, urticaria. 5. Others: amblyopia, increased CPK, dry mouth, dyspnea, epistaxis, irritability, hyperglycemia, hyperuricemia, impotence

1. Patients with sick sinus syndrome without pacemaker. 2. Patients with II or III degree atrioventricular block without pacemaker. 3. Patients with systolic blood pressure lower than 12kPa (90mmHg). 4. Patients allergic to this product. 5. Patients with acute myocardial infarction or pulmonary congestion.

Precautions for children: This experiment has not been conducted and there are no reliable references. Precautions for pregnancy and lactation: There is a lack of controlled trial data for the use of this product in pregnant women, so pregnant women must weigh the pros and cons when using this product. This product can be excreted through breast milk, and its concentration is close to the blood drug concentration. If it is necessary for lactating women to use this product, the feeding method of the baby must be changed. Precautions for the elderly: No clinical data on the use of this drug in the elderly have been found, but it is recommended that elderly patients can start taking the drug at half the normal dose.

1beta-receptor blockers: Studies have shown that diltiazem hydrochloride is well tolerated when used in combination with beta-receptor blockers, but there is insufficient data in patients with left ventricular dysfunction and conduction dysfunction. This product can increase the bioavailability of propranolol by nearly 50%, so the dose of propranolol needs to be adjusted when starting or stopping the combination of the two drugs. 2Cimetidine: Due to the inhibition of cytochrome P450 oxidase affecting the first-pass metabolism of this product, it can significantly increase the peak blood concentration of this product and the area under the drug-time curve. Ranitidine only slightly increases the blood concentration of this product. 3Digoxin: There are reports that this product can increase the blood concentration of digoxin by 20%, but there are also reports that it has no effect. Although the results are contradictory, the blood concentration of digoxin should be monitored when starting, adjusting and stopping treatment with this product to avoid excessive or insufficient digoxin. 4Anesthetics: They inhibit myocardial contraction, conduction, and automaticity, and have vasodilation effects, which can produce synergistic effects with this product. Therefore, the dose must be carefully adjusted when the two drugs are used together.

Sealed, store in a dry place.

30 mg

36 months